Scholarly Works - Book sections
Book section
·
January 1, 2026
Patients with glioblastoma (GBM) have a dismal prognosis despite the most aggressive multimodal regimen affording a median survival of barely 15 months. Thus the field is in desperate need of therapies that specifically and safely target these tumors. Armi ...
Full text
Cite
Book section
·
January 1, 2023
Drug development is a time-consuming and expensive process that often fails to translate new, exciting scientific findings into safe and effective clinical therapies. In this chapter, we outline strategies for preclinical drug testing studies, using as an ...
Full text
Cite
Book section
·
April 24, 2018
Patients with glioblastoma (GBM) have a dismal prognosis despite the most aggressive multimodal regimen affording a median survival of barely 15 months. Thus, the field is in desperate need of therapies that specifically and safely target these tumors. Arm ...
Full text
Cite
Book section
·
January 1, 2018
To achieve optimal patient outcomes in brain tumor surgery, it is critical to know how to identify, manage and prevent common complications. From specific to broad, complications can be categorized as local, regional, or systemic. Local complications depen ...
Full text
Cite
Book section
·
March 2, 2017
Despite a multimodal approach involving surgery, radiotherapy, and chemotherapy, the median survival for malignant brain tumor patients is limited to 15-19. months. To improve glioblastoma patient survival, novel therapies targeting the heterogeneous tumor ...
Full text
Cite
Book section
·
March 2, 2017
Conventional therapy for glioblastoma (GBM) fails to specifically target and eliminate tumor cells, resulting in nonspecific toxicity that limits therapeutic efficacy. In contrast, immunotherapy utilizes the immune system to eradicate tumor cells with exqu ...
Full text
Cite
Book section
·
March 2, 2017
Malignant brain tumors represent an aggressive disease entity. The lack of specificity of standard therapy damages nonmalignant tissue. These off-target effects result in both short-term and long-term complications, which limit quality of life. Exciting op ...
Full text
Cite
Book section
·
March 31, 2016
Provides a summary of glioma biology, genetics and management, based on the world-leading Duke University Preston Robert Tisch Brain Tumor Center program. ...
Link to item
Cite
Book section
·
2016
Messenger RNA (mRNA)-transfected dendritic cell (DC) vaccines have been shown to be a powerful modality for eliciting antitumor immune responses in mice and humans; however, their application has not been fully optimized since many of the factors that cont ...
Full text
Link to item
Cite
Book section
·
January 1, 2016
Malignant gliomas are the most common primary brain tumor in adults, with an incidence of five cases per 100,000 persons per year. Grade IV glioblastoma is the most aggressive form and prognosis remains poor despite the current gold-standard first-line tre ...
Full text
Cite
Book section
·
January 1, 2004
The incidence of primary brain tumors is increasing. Approximately 18,000 new cases were expected in the U.S. in 2003.1 High-grade gliomas (HGGs) including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary tumors of ...
Cite
